Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - APG-1387 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APG-1387 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.APG-1387 in Pancreatic Ductal AdenocarcinomaDrug Details:APG-1387 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Litifilimab in Acute Cutaneous Lupus Erythematosus (ACLE)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Litifilimab in Acute Cutaneous Lupus Erythematosus (ACLE) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Litifilimab in Acute Cutaneous Lupus Erythematosus (ACLE)Drug Details:BIIB-059 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Feladilimab in Hypopharyngeal Cancer Drug Details: GSK-3359609 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Feladilimab in Laryngeal Cancer Drug Details: GSK-3359609 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Risperidone in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risperidone in Lung Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risperidone in Lung Adenocarcinoma Drug Details: Risperidone (VAL-401) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Sarotalocan in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Sarotalocan in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cetuximab Sarotalocan in Recurrent Head And...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Zifanocycline in Skin And Skin Structure Infections (SSSI) Caused By Bacteria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zifanocycline in Skin And Skin Structure Infections (SSSI) Caused By Bacteria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zifanocycline in Skin And...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in B-Cell Chronic Lymphocytic Leukemia Drug Details: Nemtabrutinib (ARQ-531)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.